RxDoctor Payments Data

Robbyn Jewell

Nurse Practitioner · Greensburg, KYNPI 1356490122

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 8 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 8 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $41 and has fallen 52.9% since, to $19 in 2025. That places this record below the midpoint for nurse practitioner clinicians in KY, where the typical reported total is $266.

$127in general payments, 2019–2025

Across 8 payments — averaging $15.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$19
  • Exact Sciences$19
  • Novartis$19
  • Avanir Pharmaceuticals, Inc.$15
  • Ultragenyx Pharmaceutical Inc.$15
  • Amarin Pharma, Inc.$13
  • plus $26 from 2 others

What the payments were for

  • Food & beverage$127100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$127 in reported general payments places this provider in the 40th percentile of 1,918 nurse practitioner providers in Kentucky.

See all nurse practitioner providers in Kentucky

Medicare billing

Part B allowed, 2024
$11,748
Medicare patients
65
Services billed
389

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$64,688
RexultiBrexpiprazole11$14,316
OzempicSemaglutide12$11,330
TrulicityDulaglutide14$9,249
TradjentaLinagliptin12$6,812
Fluticasone-SalmeterolFluticasone Propion/Salmeterol34$4,750
SymbicortBudesonide/Formoterol Fumarate14$4,123
Albuterol Sulfate HfaAlbuterol Sulfate71$2,463
Lantus SolostarInsulin Glargine,hum.Rec.Anlog14$2,091
Tamsulosin Hcl94$1,766
Ventolin HfaAlbuterol Sulfate15$1,419
Atorvastatin Calcium190$1,405
Levothyroxine Sodium144$1,349
Memantine Hcl16$1,264
Pravastatin Sodium52$1,041

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$13$9,24914 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,918 nurse practitioner providers in Kentucky.

Other nurse practitioner in Greensburg

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →